Medpage Today on MSN1d
Semaglutide Tied to Small Risk of Potentially Blinding Eye Condition
The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...
Healthline3d
Trulicity and Weight Loss
Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.
Cutting NIH funding puts my life on the line — and maybe yours, as well
Private investment in pharmaceutical research can't replace the National Institutes of Health. Both public investment and the ...
Diabetes UK17d
Our response to serious supply issues of drugs for people with type 2 diabetes
The NHS had been facing supply issues with glucagon-like peptide receptor agonists (GLP-1 RAs, or GLP-1 analogues), a range of drugs used for managing blood glucose levels in people with type 2 ...
Frontiers3y
Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis
Improved mortality was associated with oral semaglutide compared with once-weekly semaglutide, albiglutide, dulaglutide, exenatide, or lixisenatide. Risks of heart failure, thyroid carcinoma, and ...
pharmaphorum7y
Novo's semaglutide outperforms Lilly GLP-1 rival
The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival, further bolsters semaglutide's profile ahead of its anticipated approval later this year as ...
Medscape10y
Once-Weekly Dulaglutide Effective for T2DM
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...